Contact
searchSearch
HMP Global
Poll

Cardiovascular Disease Risk in Young Adults

12/15/2023

Learn more about how cardiovascular disease can affect younger patients and how health care professionals can take the initiative to reach a diagnosis.


Related Content

News
FDA Class III Recall Issued for Pitavastatin Tablets Due to Mixed Dosage Tablet in Bottle
03/19/2026
Grace Taylor, MS, MA
A nationwide alert has been issued after a mislabeled bottle of pitavastatin was found to contain a lower-dose tablet, prompting a Class III recall affecting select inventory in Tennessee.
A nationwide alert has been issued after a mislabeled bottle of pitavastatin was found to contain a lower-dose tablet, prompting a Class III recall affecting select inventory in Tennessee.
A nationwide alert has been...
03/19/2026
Pharmacy Learning Network
Talking Therapeutics
Talking Therapeutics
No CLEAR Advantage for Spironolactone in STEMI Patients
12/13/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this installment of Talking Therapeutics, we discuss an important study addressing the effects of spironolactone in a pure STEMI cohort.
In this installment of Talking Therapeutics, we discuss an important study addressing the effects of spironolactone in a pure STEMI cohort.
In this installment of Talking...
12/13/2024
Pharmacy Learning Network
Douglas Jennings
Talking Therapeutics
Another Win for GLP-1 Receptor Agonists: Treatment for Patients With Diabetes and CKD
06/06/2024
Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS
In this week's installment of Talking Therapeutics, Dr Jennings explores a new trial that evaluates the impact of GLP-1 agonists on kidney and cardiovascular endpoints in patients with diabetes and chronic kidney disease.
In this week's installment of Talking Therapeutics, Dr Jennings explores a new trial that evaluates the impact of GLP-1 agonists on kidney and cardiovascular endpoints in patients with diabetes and chronic kidney disease.
In this week's installment of...
06/06/2024
Pharmacy Learning Network
Headshot of Mark Munger, PharmD, University of Utah
Commentary
High-Density Lipoprotein Cholesterol and Risk of Fractures in Healthy Older Adults
02/21/2023
Mark A. Munger, PharmD, FCCP, FACC, FHFSA
“There remains a need for a prospective, randomized clinical trials to confirm whether HDL-C causes bone fractures in older adults,” says Mark Munger, PharmD, FCCP, FACC, FHFSA.
“There remains a need for a prospective, randomized clinical trials to confirm whether HDL-C causes bone fractures in older adults,” says Mark Munger, PharmD, FCCP, FACC, FHFSA.
“There remains a need for a...
02/21/2023
Pharmacy Learning Network

Subscribe Today

Pharmacy Learning Network Newsletter

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use